{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-007294","form_type":"8-K","ticker":"ZIVO","cik":"0001101026","company_name":"Zivo Bioscience, Inc.","filed_at":"2023-05-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.940772+00:00","generated_at":"2026-06-14T12:32:43.287470+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zivo Bioscience receives Nasdaq delisting notice for $2.5M equity non-compliance","bullets":["Nasdaq notified Zivo on May 23, 2023 that it fails to meet $2.5M stockholders' equity requirement (Listing Rule 5550(b)).","Company plans to request a hearing before Nasdaq Hearings Panel to stay delisting pending compliance plan.","Previously granted extension to evidence compliance expired May 22, 2023; company was unable to cure.","No assurance that Panel will grant continued listing or that company can regain compliance within any extension."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-007294","json":"https://secwatch.observer/filing/0001654954-23-007294.json","markdown":"https://secwatch.observer/filing/0001654954-23-007294.md","text":"https://secwatch.observer/filing/0001654954-23-007294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423007294/0001654954-23-007294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423007294/zivo_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:32:43.287470+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"368f5b206b1eb3b50b6988b69f111ae499f73768","claim":"Zivo Bioscience, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).","evidence_excerpt":"May 23, 2023, Zivo Biosciences, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b) (the “Rule”), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing bef","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423007294/0001654954-23-007294-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}